StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3069% below fair value
$1.40−0.14 (-9.09%)

Close on Nov 20, 2026Market cap $3.28MP/E –Yield –

Xenetic Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Xenetic Biosciences's free cash flow for the twelve months ending Dec 31, 2018 was -$6.46M, down 535.3% year over year. For fiscal 2018 it was -$6.46M, down 535.3% from the year before. The highest annual figure on record is $1.48M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2018Dec 31, 2018-$6.46M-535.3%
FY2017Dec 31, 2017$1.48M–
FY2016Dec 31, 2016-$8.80M–
FY2015Dec 31, 2015-$5.30M–
FY2014Dec 31, 2014-$12.74M–
FY2013Dec 31, 2013-$6.13M–
FY2012Dec 31, 2012-$6.39M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2018Dec 31, 2018-$1.04M-121.5%
Q3 FY2018Sep 30, 2018-$1.67M–
Q2 FY2018Jun 30, 2018-$2.09M–
Q1 FY2018Mar 31, 2018-$1.67M-705.3%
Q4 FY2017Dec 31, 2017$4.84M–
Q3 FY2017Sep 30, 2017-$1.64M–
Q2 FY2017Jun 30, 2017-$1.99M–
Q1 FY2017Mar 31, 2017$275.38K–
Q4 FY2016Dec 31, 2016-$4.63M–
Q3 FY2016Sep 30, 2016-$1.03M–
Q2 FY2016Jun 30, 2016-$1.36M–

More Xenetic Biosciences figures

See a number that looks wrong?